ClinicalTrials.gg
RecruitingNCT07288359Updated Oct 29, 2026

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase 1/2 interventional study of GVV858 and Fulvestrant in Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors and Metastatic Castration-resistant Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 16 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 29, 2026First site in CanadaEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 199 studies in Breast Neoplasms by Novartis — 16 open to participants now, 30 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
56th of 155
205 · median 104
Started
2025
with 7 others
Phase 1/2
12 of 199
2 open now
Primary completion
2031-05
later than 25 of 29 live
Registered
187th of 199
by date

Among the 199 studies in Breast Neoplasms by Novartis, this one is the 56th largest by planned enrollment of the 155 interventional ones that give a count, is one of 8 that started in 2025, is one of 12 in phase 1/2, reaches primary completion later than 25 of the 29 other live ones, and was the 187th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 199 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.

Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Read the detailed description

This is a first-in-human, open-label, phase I/II, multi-center study consisting of a GVV858 single agent treatment arm in patients with advanced HR+/HER2- breast cancer, other advanced solid tumors harboring CCNE1 amplification, and metastatic castration-resistant prostate cancer, and a combination treatment arm of GVV858 with fulvestrant or letrozole in patients with advanced HR+/HER2- breast cancer. Single agent escalation may be followed by an expansion part stratified by disease indication. The escalation of the fulvestrant combination arm may continue into a randomized, open label, Phase II with optional dose optimization in advanced HR+/HER2- breast cancer patients.

03

Conditions studied

  • Advanced HR+/HER2- Breast Cancer
  • Advanced CCNE1-amplified Solid Tumors
  • Metastatic Castration-resistant Prostate Cancer

Keywords

  • GVV858
  • Fulvestrant
  • Letrozole
  • Breast Cancer
  • CCNE1 amplification
  • Prostate Cancer
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old.
  • Patients with one of the following or cytologically confirmed advanced cancers:
  • Phase I (patients with one of the following cancers, from whom no standard therapy is available or appropriate in the judgment of the investigator):

    • HR+/- advanced breast cancer (aBC) with disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i and at least one additional for disease.
    • Locally advanced or metastatic cancer with a CCNE1 amplification. For dose expansion only: no more than 3 prior lines of therapy for advanced or metastatic disease.
    • Metastatic castration-resistant prostate adenocarcinoma (mCRPC), with no documented neuroendocrine component, castrate level of testosterone. For dose expansion only: no more than 3 prior lines of systemic therapy for metastatic disease.
  • Phase II:

    • HR+/HER2- aBC with disease progression on or after an endocrine therapy in combination, with a CDK4/6 inhibitor for advanced disease with no more than 2 lines of endocrine therapy and no prior cytotoxic chemotherapy or antibody-drug-conjugate for advanced disease.
  • as determined by v1.1.

    • BC only: If no measurable disease is present, then at least one predominantly lytic bone lesion must be present that can be accurately assessed at baseline and is suitable for repeated assessment.
    • mCRPC only: If no measurable disease is present per PCWG3 modified RECIST, then at least 1 metastatic lesion must be present on bone scan imaging.

Exclusion criteria

Exclusion Criteria:

  • Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values.
  • , uncontrolled heart disease and/or cardiac repolarization abnormality including myocardial infarction (MI), coronary artery bypass graft (CABG), long syndrome, or risk factors for Torsades de Pointes (TdP).
  • Presence of symptomatic central nervous system (CNS) or that require local therapy or increasing doses of within 2 weeks prior to study entry.
  • Patients with visceral crisis.
  • For patients with BC: Patient is concurrently using hormone replacement therapy.
  • Women of who are unwilling to use highly effective methods, pregnant or nursing women.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
205 participants (estimated)

Study arms

  • Experimental
    GVV858 Single Agent (Arm A)

    Phase I

    Drug: GVV858

  • Experimental
    GVV858 in combination with fulvestrant (Arm B)

    Phase I

    Drug: GVV858 · Drug: Fulvestrant

  • Experimental
    GVV858 in combination with letrozole (Arm C)

    Phase I

    Drug: GVV858 · Drug: Letrozole

  • Experimental
    GVV858 in combination with fulvestrant (Arm D)

    Phase II, recommended dose regimen 1 (optional dose optimization)

    Drug: GVV858 · Drug: Fulvestrant

  • Experimental
    GVV858 in combination with fulvestrant (Arm E)

    Phase II, recommended dose regimen 2 (optional dose optimization)

    Drug: GVV858 · Drug: Fulvestrant

Interventions

  • DrugGVV858

    Experimental

  • Approved medication

    Also known as: Faslodex

  • Approved medication

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Phase I: Incidence and severity of dose-limiting toxicities (DLTs)

    Number of participants with DLTs. A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher, unless clearly and inconvertibly assessed as due to disease progression, inter-current illness/injury, concomitant medications, or extraneous causes, that occurs within the first 28 days of treatment in the Phase 1 part. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

    Time frame: 28 days

  2. Phase I and phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: Up to approximately 2 years

  3. Phase I and phase II: Frequency of dose interruptions, reductions and discontinuations

    Number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) as a measure of tolerability.

    Time frame: Up to approximately 2 years

  4. Phase I and phase II: Dose intensity

    The dose intensity of each study drug is computed as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Phase I and II: Peak plasma concentration (Cmax) of GVV858

    Pharmacokinetic (PK) parameters calculated based on GVV858 plasma concentrations.

    Time frame: Cycle 1 Day 1 and/or Day 21: From pre-dose up to maximum 24 hours post dose. The duration of one cycle is 28 days.

  2. Phase I and II: Time to reach peak plasma concentration (Tmax) of GVV858

    PK parameters calculated based on GVV858 plasma concentrations.

    Time frame: Cycle 1 Day 1 and/or Day 21: From pre-dose up to maximum 24 hours post dose. The duration of one cycle is 28 days.

  3. Phase I and II: Area under the plasma concentration-time curve (AUC) of GVV858

    PK parameters calculated based on GVV858 plasma concentrations.

    Time frame: Cycle 1 Day 1 and/or Day 21: From pre-dose up to maximum 24 hours post dose. The duration of one cycle is 28 days.

  4. Phase I and Phase II: Overall response rate (ORR)

    Tumor response assessed by the investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or Prostate Cancer Working Group 3 (PCWG3) criteria including PCWG3-modified RECIST v1.1. (only for patients with prostate cancer). ORR per RECIST v1.1 is defined as the proportion of patients with a best overall response of Complete response (CR) or Partial response (PR) according to RECIST v1.1 as per local review.

    Time frame: Up to approximately 2 years

  5. Phase I and Phase II: Best overall response (BOR)

    Tumor response assessed by the investigator based on based on RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1. (only for patients with prostate cancer). BOR per RECIST v1.1 is defined as the best overall confirmed response recorded from the start of the treatment until progressive disease (PD), death, start of new therapy, withdrawal of consent or end of study, whatever comes first.

    Time frame: Up to approximately 2 years

  6. Phase I and Phase II: Disease control rate (DCR)

    Tumor response assessed by the investigator based on based on RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1. (only for patients with prostate cancer). DCR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or Stable disease (SD) according to RECIST v1.1 as per local review.

    Time frame: Up to approximately 2 years

  7. Phase I and Phase II: Clinical benefit rate (CBR)

    Tumor response assessed by the investigator based on based on RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1. (only for patients with prostate cancer). CBR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or an overall lesion response of SD or Non-CR/Non-PD which lasts for at least 24 weeks according to RECIST v1.1 as per local review.

    Time frame: Up to approximately 2 years

  8. Phase I and Phase II: Progression free survival (PFS)

    Tumor response assessed by the investigator based on based on RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1. (only for patients with prostate cancer). PFS per RECIST 1.1 is defined as the time from the date of start of study treatment (phase I) or the date of randomization (Phase II) to the date of the first documented progression or death due to any cause.

    Time frame: Up to approximately 2 years

  9. Phase II: Duration of response (DOR)

    Tumor response assessed by the investigator based on based on RECIST v1.1, or PCWG3 criteria including PCWG3-modified RECIST v1.1. (only for patients with prostate cancer). DOR per RECIST v1.1 is the time between the first documented response (CR or PR) and the date of progression by local review as applicable or death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

16 of 16 sites recruiting
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
    Recruiting
  • START
    San Antonio, Texas 78229, United States
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • Novartis Investigative Site
    Olomouc, 779 00, Czechia
    Recruiting
  • Novartis Investigative Site
    Odense C, 5000, Denmark
    Recruiting
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
    Recruiting
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
    Recruiting
  • Novartis Investigative Site
    Essen, 45147, Germany
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20141, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20162, Italy
    Recruiting
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
    Recruiting
  • Novartis Investigative Site
    Singapore, 168583, Singapore
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08035, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28041, Spain
    Recruiting
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2031, 64 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 64 months is close to that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartActual
Dec 29, 2025
Primary completionEst.
May 9, 2031
CompletionEst.
May 9, 2031
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Canada
Show site
  • Novartis Investigative Site · Toronto, Canada
Oct 9, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedMetastatic castration-resistant prostate adenocarcinoma (mCRPC), with no documented neuroendocrine component, castrate level of testosterone, and. For dose expansion only: no more than 3 prior lines of systemic therapy for metastatic disease.
  • Editedmetastatic Castration-Resistant Prostate Cancer (mCRPC) only: If no measurable disease is present per PCWG3 modified RECIST, then at least 1 metastatic lesion must be present on bone scan imaging.
Exclusion criteria
  • EditedPatients with symptomatic visceral disease, including visceral crisis.
Oct 29, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Emory University · Atlanta, United StatesContact s•••@emory.edu→k•••@emoryhealthcare.org
  • Tennessee Oncology PLLC · Nashville, United StatesContact h•••@tnonc.com→c•••@tnonc.com
  • START · San Antonio, United StatesContact •••5250→•••5250
across 2 updates, Oct 9, 2026 – Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedMetastatic castration-resistant prostate adenocarcinoma (mCRPC), with no documented neuroendocrine component, castrate level of testosterone, and. For dose expansion only: no more than 3 prior lines of systemic therapy for metastatic disease.
    • Editedmetastatic Castration-Resistant Prostate Cancer (mCRPC) only: If no measurable disease is present per PCWG3 modified RECIST, then at least 1 metastatic lesion must be present on bone scan imaging.
    Exclusion criteria
    • EditedPatients with symptomatic visceral disease, including visceral crisis.
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Emory University · Atlanta, United StatesContact s•••@emory.edu→k•••@emoryhealthcare.org
    • Tennessee Oncology PLLC · Nashville, United StatesContact h•••@tnonc.com→c•••@tnonc.com
    • START · San Antonio, United StatesContact •••5250→•••5250
    + 1 other change: arm descriptions
  2. Oct 9, 2026
    1 site added — first site in Canada
    Show site
    • Novartis Investigative Site · Toronto, Canada
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Emory University · Atlanta, United StatesContact k•••@emoryhealthcare.org→s•••@emory.edu
    • Tennessee Oncology PLLC · Nashville, United StatesContact c•••@tnonc.com→h•••@tnonc.com
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07288359
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 29, 2025
Primary completion
May 9, 2031 (estimated)
Completion
May 9, 2031 (estimated)
Last update
Oct 29, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion